Jay F. Sarthy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jay F. Sarthy has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
- Steven Henikoff
Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
46 shared publications - Kami Ahmad
Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
41 shared publications - Derek Henry Janssens
Department of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA
38 shared publications - Michael P. Meers
Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA
37 shared publications - Anna-Lisa Doebley
Division of Public Health Sciences Fred Hutchinson Cancer Center 1100 Fairview Ave. N 98109 Seattle WA
34 shared publications - Arnab Bose
Division of Human Biology Fred Hutchinson Cancer Center 1100 Fairview Ave. N 98109 Seattle WA
34 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Genome-wide CRISPR-screening identifies p53 as regulator of cancer cell sensitivity to the histone evicting anthracycline aclarubicin
The anthracycline family, with its prime member doxorubicin, is one of the cornerstones in cancer chemotherapy and acts by poisoning topoisomerase II, resulting in DNA double-stranded breaks. One of its members, aclarubicin, is considered a distinct member of this family due to its inability to inflict DNA double-strand breaks. Despite this, aclarubicin is an effective anti-cancer drug by evicting histones, resulting in chromatin damage. How aclarubicin-induced chromatin damage induces cell death remains largely unknown. Here, we performed a genome-wide CRISPR screen to identify factors regulating sensitivity of cells to aclarubicin and identified p53 as a critical factor for cellular sensitivity. Even though aclarubicin does not induce DNA breaks, treatment resulted in swift activation of ATM independent of the MRN complex, which stabilized and activated p53, resulting in apoptosis and cell cycle arrest. Furthermore, response to aclarubicin treatment could reasonably be predicted by the p53-status of cell lines. These data suggest that ATM and p53 can be activated for apoptosis induction by at least two different pathways, DNA- and chromatin damage. Together, these data suggest p53 could be an important factor to stratify patients for treatment with Aclarubicin.
- 5 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessGenome-wide CRISPR-screening identifies p53 as regulator of cancer cell sensitivity to the histone evicting anthracycline aclarubicin
The anthracycline family, with its prime member doxorubicin, is one of the cornerstones in cancer chemotherapy and acts by poisoning topoisomerase II, resulting in DNA double-stranded breaks. One of its members, aclarubicin, is considered a distinct member of this family due to its inability to inflict DNA double-strand breaks. Despite this, aclarubicin is an effective anti-cancer drug by evicting histones, resulting in chromatin damage. How aclarubicin-induced chromatin damage induces cell death remains largely unknown. Here, we performed a genome-wide CRISPR screen to identify factors regulating sensitivity of cells to aclarubicin and identified p53 as a critical factor for cellular sensitivity. Even though aclarubicin does not induce DNA breaks, treatment resulted in swift activation of ATM independent of the MRN complex, which stabilized and activated p53, resulting in apoptosis and cell cycle arrest. Furthermore, response to aclarubicin treatment could reasonably be predicted by the p53-status of cell lines. These data suggest that ATM and p53 can be activated for apoptosis induction by at least two different pathways, DNA- and chromatin damage. Together, these data suggest p53 could be an important factor to stratify patients for treatment with Aclarubicin.
- Open Access
MSstatsBioNet: Integrating Statistical Analyses with Prior Knowledge Biomolecular Networks for Quantitative Proteomics and Phosphoproteomics
A common outcome of quantitative mass spectrometry-based proteomic and phosphoproteomic experiments is a list of proteins that are differentially abundant between conditions. However, biological interpretation requires evaluation in the context of prior knowledge of biological mechanisms and protein function. One approach to facilitate mechanistic biological interpretation is to integrate such lists with biological network databases, built from manually curated resources and text mining systems. This manuscript automates this process with MSstatsBioNet, a Bioconductor package that integrates MSstats, a family of open-source packages for detecting differentially abundant proteins, and INDRA, a system that extracts biomolecular networks from biomedical literature using text mining and merges those networks with the content of curated knowledge bases. Taking as input a list of differentially abundant proteins from MSstats, MSstatsBioNet retrieves a protein subnetwork from INDRA and overlays experimental fold changes onto the underlying subnetwork. Users can then interact with the network and overlaid data, interrogating primary literature evidence to construct granular mechanistic narratives for iterative hypothesis generation. We demonstrate the utility of this approach with three case studies, two measuring changes in protein abundance and one measuring changes in phosphorylation.
Open AccessMSstatsBioNet: Integrating Statistical Analyses with Prior Knowledge Biomolecular Networks for Quantitative Proteomics and Phosphoproteomics
A common outcome of quantitative mass spectrometry-based proteomic and phosphoproteomic experiments is a list of proteins that are differentially abundant between conditions. However, biological interpretation requires evaluation in the context of prior knowledge of biological mechanisms and protein function. One approach to facilitate mechanistic biological interpretation is to integrate such lists with biological network databases, built from manually curated resources and text mining systems. This manuscript automates this process with MSstatsBioNet, a Bioconductor package that integrates MSstats, a family of open-source packages for detecting differentially abundant proteins, and INDRA, a system that extracts biomolecular networks from biomedical literature using text mining and merges those networks with the content of curated knowledge bases. Taking as input a list of differentially abundant proteins from MSstats, MSstatsBioNet retrieves a protein subnetwork from INDRA and overlays experimental fold changes onto the underlying subnetwork. Users can then interact with the network and overlaid data, interrogating primary literature evidence to construct granular mechanistic narratives for iterative hypothesis generation. We demonstrate the utility of this approach with three case studies, two measuring changes in protein abundance and one measuring changes in phosphorylation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Supplementary Figures S1-S18 and Supplementary Table legends.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Supplementary Figures S1-S18 and Supplementary Table legends.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PDX sequencing metrics Phenotype and sequencing metrics for all PDX LuCaP lines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PDX sequencing metrics Phenotype and sequencing metrics for all PDX LuCaP lines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PTM peak data and phenotype 47 fragment variability Sheet 1: PDX sample representation in 3 histone PTM CUT&RUN nucleosome profiling assays (H3K4me1, H2K27ac and H3K27me3). Sheet 2: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene promoters (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
PTM peak data and phenotype 47 fragment variability Sheet 1: PDX sample representation in 3 histone PTM CUT&RUN nucleosome profiling assays (H3K4me1, H2K27ac and H3K27me3). Sheet 2: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene promoters (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Feature-region combination AUCs and benchmarking Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in all queried (338) TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘AR10’ overlapping features (see Methods). Sheet 3: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘Phenotype 47-defining’ overlapping features. Sheet 4: 100-fold cross-validation AUCs for all region and feature combinations (global). Sheet 5: Predictions scores, tumor fraction, depth of coverage, and subtype for benchmarking admixtures. Sheet 6: AUCs for unsupervised prediction of admixture subtypes grouped by tumor fraction and depth. Sheet 7: NEPC:ARPC ratio, tumor fraction, and ARPC and NEPC fraction predictions for mixed phenotype admixtures using Keraon (see Methods).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Feature-region combination AUCs and benchmarking Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in all queried (338) TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘AR10’ overlapping features (see Methods). Sheet 3: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘Phenotype 47-defining’ overlapping features. Sheet 4: 100-fold cross-validation AUCs for all region and feature combinations (global). Sheet 5: Predictions scores, tumor fraction, depth of coverage, and subtype for benchmarking admixtures. Sheet 6: AUCs for unsupervised prediction of admixture subtypes grouped by tumor fraction and depth. Sheet 7: NEPC:ARPC ratio, tumor fraction, and ARPC and NEPC fraction predictions for mixed phenotype admixtures using Keraon (see Methods).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Differential regulation metrics and values for select features Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for NPS in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: Differentially expressed list of 514 transcription factor (TF). All statistical comparison and fold change estimation was done against ARPCs. Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in 108 TFs overlapping RNA-Seq up/down regulated TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 4: Paralogous transcription factors (TFs) for each of the 38 TFs with differential RNA expression between ARPC and NEPC and differential TFBS accessibility. Paralogous TFs that are also differentially expressed by RNAseq analysis of PDX tumors are shown in red text. Paralogs were obtained from ensembl biomart human genes GRCh38.p13 (http://uswest.ensembl.org/biomart/martview/64d8bd7fe9851a2501aece9b74b03631) Sheet 5: Mean values in ARPC, NEPC, and HD lines for central and window means for ARPC and NEPC specific open chromatin regions.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Differential regulation metrics and values for select features Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for NPS in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: Differentially expressed list of 514 transcription factor (TF). All statistical comparison and fold change estimation was done against ARPCs. Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in 108 TFs overlapping RNA-Seq up/down regulated TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 4: Paralogous transcription factors (TFs) for each of the 38 TFs with differential RNA expression between ARPC and NEPC and differential TFBS accessibility. Paralogous TFs that are also differentially expressed by RNAseq analysis of PDX tumors are shown in red text. Paralogs were obtained from ensembl biomart human genes GRCh38.p13 (http://uswest.ensembl.org/biomart/martview/64d8bd7fe9851a2501aece9b74b03631) Sheet 5: Mean values in ARPC, NEPC, and HD lines for central and window means for ARPC and NEPC specific open chromatin regions.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Unsupervised model predictions and patient/validation cohort sequencing metrics Sheet 1: DFCI Cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 2: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using ctdPheno. Sheet 3: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using Keraon. Sheet 4: DFCI Cohort II: Tumor phenotype by histology, summary of clinical correlatives and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 5: Histology, tumor fraction, subtype score, NEPC fraction, and subtype calls for WGS and ULP patient samples (UW cohort). Sheet 6: Complete sequencing metrics for DFCI cohort I. Sheet 7: Complete sequencing metrics for DFCI cohort II (ULP). Sheet 8: Complete sequencing metrics for DFCI cohort II (deep WGS) Sheet 9: Complete sequencing metrics and ichorCNA estimated tumor fractions for the UW cohort (ULP). Sheet 10: Complete sequencing metrics for the UW cohort (deep WGS) Sheet 11: Complete sequencing metrics for the healthy donor cohort. Sheet 12: Clinical data summary for UW cohort.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Unsupervised model predictions and patient/validation cohort sequencing metrics Sheet 1: DFCI Cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 2: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using ctdPheno. Sheet 3: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using Keraon. Sheet 4: DFCI Cohort II: Tumor phenotype by histology, summary of clinical correlatives and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 5: Histology, tumor fraction, subtype score, NEPC fraction, and subtype calls for WGS and ULP patient samples (UW cohort). Sheet 6: Complete sequencing metrics for DFCI cohort I. Sheet 7: Complete sequencing metrics for DFCI cohort II (ULP). Sheet 8: Complete sequencing metrics for DFCI cohort II (deep WGS) Sheet 9: Complete sequencing metrics and ichorCNA estimated tumor fractions for the UW cohort (ULP). Sheet 10: Complete sequencing metrics for the UW cohort (deep WGS) Sheet 11: Complete sequencing metrics for the healthy donor cohort. Sheet 12: Clinical data summary for UW cohort.
- Open Access
A protocol for high-throughput microplate-based CUT&Tag
Cleavage Under Targets & Tagmentation (CUT&Tag) is a versatile method for measuring genomic occupancy of chromatin-associated proteins with high sensitivity and specificity. CUT&Tag has low sequencing requirements and is therefore suitable for highly multiplexed experiments, but methods to process samples at throughput without specialized equipment are lacking. Here we present a method for simultaneous parallel processing of 96 CUT&Tag samples in a standard microplate. Plate-CUT&Tag can be carried out in a similar time frame to benchtop CUT&Tag and yields data of comparable quality. We present data from cell culture and patient leukemia samples processed with Plate-CUT&Tag to illustrate its utility in large-scale preclinical and translational studies.
Open AccessA protocol for high-throughput microplate-based CUT&Tag
Cleavage Under Targets & Tagmentation (CUT&Tag) is a versatile method for measuring genomic occupancy of chromatin-associated proteins with high sensitivity and specificity. CUT&Tag has low sequencing requirements and is therefore suitable for highly multiplexed experiments, but methods to process samples at throughput without specialized equipment are lacking. Here we present a method for simultaneous parallel processing of 96 CUT&Tag samples in a standard microplate. Plate-CUT&Tag can be carried out in a similar time frame to benchtop CUT&Tag and yields data of comparable quality. We present data from cell culture and patient leukemia samples processed with Plate-CUT&Tag to illustrate its utility in large-scale preclinical and translational studies.
- Open Access
Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contribute to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development. Summary: Multimodal transcriptional analysis reveal how Ewing sarcoma tumors use distinct gene programs, including one linked to TGF-β, to drive cancer behavior and progression.
Open AccessMultimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contribute to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development. Summary: Multimodal transcriptional analysis reveal how Ewing sarcoma tumors use distinct gene programs, including one linked to TGF-β, to drive cancer behavior and progression.